Edition:
United States

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

11.85USD
16 Oct 2018
Change (% chg)

-- (--)
Prev Close
$11.85
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
99,353
52-wk High
$14.62
52-wk Low
$6.60

Chart for

About

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR,... (more)

Overall

Beta: 1.08
Market Cap(Mil.): $1,246.29
Shares Outstanding(Mil.): 94.42
Dividend: --
Yield (%): --

Financials

  ADAP.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -0.99 -- --
ROI: -43.84 1.96 12.83
ROE: -47.00 1.12 14.95

BRIEF-Adaptimmune Reports Q1 Loss Per Share $0.04

* ADAPTIMMUNE REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE

May 09 2018

Earnings vs. Estimates